American International Group Inc. grew its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 3.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 561,961 shares of the biopharmaceutical company’s stock after buying an additional 18,256 shares during the period. American International Group Inc.’s holdings in Bristol-Myers Squibb were worth $34,887,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of BMY. CSat Investment Advisory L.P. bought a new stake in Bristol-Myers Squibb during the 2nd quarter valued at approximately $113,000. Cypress Capital Management LLC WY raised its stake in Bristol-Myers Squibb by 154.7% during the 3rd quarter. Cypress Capital Management LLC WY now owns 1,910 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 1,160 shares during the period. Landaas & Co. WI ADV bought a new stake in Bristol-Myers Squibb during the 2nd quarter valued at approximately $131,000. Selective Wealth Management bought a new stake in Bristol-Myers Squibb during the 3rd quarter valued at approximately $184,000. Finally, LFA Lugano Financial Advisors SA raised its stake in Bristol-Myers Squibb by 85.8% during the 3rd quarter. LFA Lugano Financial Advisors SA now owns 3,207 shares of the biopharmaceutical company’s stock valued at $199,000 after purchasing an additional 1,481 shares during the period. 72.90% of the stock is currently owned by hedge funds and other institutional investors.

NYSE:BMY opened at $53.20 on Thursday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.40 and a current ratio of 1.53. Bristol-Myers Squibb Co has a 1 year low of $46.94 and a 1 year high of $70.05. The company has a market capitalization of $87.29 billion, a price-to-earnings ratio of 17.67, a PEG ratio of 1.49 and a beta of 1.08.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.91 by $0.18. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. The business had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. On average, equities analysts expect that Bristol-Myers Squibb Co will post 3.88 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, November 1st. Shareholders of record on Friday, October 5th were paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 3.01%. The ex-dividend date of this dividend was Thursday, October 4th. Bristol-Myers Squibb’s payout ratio is 53.16%.

BMY has been the topic of several recent analyst reports. Morgan Stanley decreased their target price on Bristol-Myers Squibb from $63.00 to $59.00 and set a “hold” rating on the stock in a research note on Tuesday, November 6th. Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $70.00 target price on the stock in a research note on Friday, October 5th. Guggenheim initiated coverage on Bristol-Myers Squibb in a research note on Monday, October 8th. They set a “neutral” rating on the stock. BMO Capital Markets decreased their target price on Bristol-Myers Squibb from $57.00 to $54.00 and set a “market perform” rating on the stock in a research note on Tuesday, October 23rd. Finally, JPMorgan Chase & Co. lifted their target price on Bristol-Myers Squibb from $70.00 to $74.00 and gave the company an “overweight” rating in a research note on Monday, October 8th. Three analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $61.84.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/11/22/american-international-group-inc-has-34-89-million-stake-in-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Featured Story: Balanced Fund

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.